383 related articles for article (PubMed ID: 36922354)
1. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Bath NM; Pawlik TM
Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
[TBL] [Abstract][Full Text] [Related]
2. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
3. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK; Bridgewater J; Gores GJ; Zhu AX
J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
[TBL] [Abstract][Full Text] [Related]
5. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
Becht R; Wasilewicz MP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
[TBL] [Abstract][Full Text] [Related]
6. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors.
Wu T; Jiang X; Zhang X; Wu B; Xu B; Liu X; Zheng L; Wang Y
Cancer Control; 2021; 28():1073274821989314. PubMed ID: 33618536
[TBL] [Abstract][Full Text] [Related]
7. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
[TBL] [Abstract][Full Text] [Related]
8. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
Merath K; Tiwari A; Parikh AA; Pawlik TM
Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
[TBL] [Abstract][Full Text] [Related]
10. Liver resection and transplantation for intrahepatic cholangiocarcinoma.
Mazzaferro V; Gorgen A; Roayaie S; Droz Dit Busset M; Sapisochin G
J Hepatol; 2020 Feb; 72(2):364-377. PubMed ID: 31954498
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
12. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
13. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
14. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
15. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
16. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies.
Ruff SM; Pawlik TM
Front Oncol; 2024; 14():1321683. PubMed ID: 38344197
[TBL] [Abstract][Full Text] [Related]
18. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.
Moris D; Palta M; Kim C; Allen PJ; Morse MA; Lidsky ME
CA Cancer J Clin; 2023 Mar; 73(2):198-222. PubMed ID: 36260350
[TBL] [Abstract][Full Text] [Related]
19. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
Brown ZJ; Ruff SM; Pawlik TM
Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
[TBL] [Abstract][Full Text] [Related]
20. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
Luvira V; Satitkarnmanee E; Pugkhem A; Kietpeerakool C; Lumbiganon P; Pattanittum P
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD012814. PubMed ID: 34515993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
